Patents by Inventor Abdallah Cherif

Abdallah Cherif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anthracycline analogues bearing latent alkylating substituents
    Patent number: 6433150
    Abstract: Compound having the structure where anthracycline, N, Ra, X, Rb, n and m are as defined in the specification. The compound of the invention is activatable in vivo by esterases and spontaneous dehydration to form an aldehyde. The aldehyde may couple to nucleophiles of intracellular macromolecules. The compounds of the invention are cytotoxically effective in the inhibition of human myeloma cells.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: August 13, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: David Farquhar, Abdallah Cherif
  • Anthracycline analogues bearing latent alkylating substituents
    Publication number: 20010053845
    Abstract: Compound having the structure 1
    Type: Application
    Filed: March 2, 2001
    Publication date: December 20, 2001
    Applicant: Board of Regents
    Inventors: David Farquhar, Abdallah Cherif
  • Methods of treatment with anthracycline derivatives
    Patent number: 6284737
    Abstract: The present invention is a compound having the structure where: anthracycline is doxorubicin, daunorubicin or a derivative thereof; N is the 3′ nitrogen of daunosamine; Ra is H or alkyl; X is, O, S, CRc2 or NRc where Rc is H or alkyl; Rb is alkyl or aryl; n is 1 to 6; and m is 0 to 6. Ra and Rc are preferably H, methyl, ethyl, propyl or butyl, although other alkyl substituents are usable. Rb is alkyl or aryl. The compound of the present invention as described above is activatable in vivo by esterases and spontaneous dehydration to form an aldehyde. The aldehyde may couple to nucleophiles of intracellular macromolecules. The compounds of the present invention are cytotoxically effective in the inhibition of human myeloma cells.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: September 4, 2001
    Assignee: Pro-Neuron, Inc.
    Inventors: David Farquhar, Abdallah Cherif
  • Rapid synthesis and use of 18F-fluoromisonidazole and analogs
    Patent number: 5886190
    Abstract: The present invention involves a rapid synthesis of .sup.18 F-FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'-imidazolyl)-2-0-acetyl-3-0-tosylpropanol, glycerol-1,3-ditosylate-2-0-acetylate, 1-(2'-nitro-1'-imidazolyl)-2,3-0-diacetyl-4-0-tosylbutanol and threitol 1,4-di-tosylate-2,3-0-diacetylate, are also important aspects of the invention.A further aspect of the invention is the development of a hydrophilic PET ligand to image tumor hypoxia. Erythrotosyl analogue of 2-nitroimidazone (Ts-ETNIM) was prepared from a mixture of 2-nitromidazole, ditosylthreitol and cesium carbonate at 60.degree. C. for 1 hr. Ts-ETNIM was isolated at 70% yield. ?.sup.18 F!fluoroerythronitroimidazole (FETNIM) was then prepared from Ts-ETNIM and K.sup.18 F/kryptofix.RTM.. The yield for ?.sup.18 F!FETNIM was 26-30% (60 min, decay corrected). Results of biodistribution and PET studies indicate that ?.sup.18 F!FETNIM has the potential to detect tumor hypoxia and is indicated to be less neurotoxic.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 23, 1999
    Inventors: Sidney Wallace, David J. Yang, Abdallah Cherif
  • (2'-nitro-1'-imidazolyl)-2,3-isopropylidene-y-tosylbutanol, a precursor to ?.sup.18 F!fluoroerythronitroimidazole PET imaging agent
    Patent number: 5728843
    Abstract: The present invention involves a rapid synthesis of .sup.18 F-FMISO and analogs thereof. New precursors such as 1-(2'-nitro-1'-imidazolyl)-2-0-acetyl-3-0-tosylpropanol, glycerol-1,3-ditosylate-2-0-acetylate, 1-(2'-nitro-1'-imidazolyl)-2,3-0-diacetylate, are also important aspects of the invention.A further aspect of the invention is the development of a hydrophilic PET ligand to image tumor hypoxia. Erythrotosyl analogue of 2-nitroimidazone (Ts-ETNIM) was prepared from a mixture of 2-nitromidazole, ditosylthreitol and cesium carbonate at 60.degree. C. for 1 hr. Ts-ETNIM was isolated at 70% yield. ?.sup.18 F!fluoroerythronitroimidazole (FETNIM) when prepared from Ts-ETNIM and K.sup.18 F/kryptofix.RTM.. The yield for ?.sup.18 F!FETNIM was 26-30% (60 min, decay corrected). Results of biodistribution and PET studies indicate that ?.sup.18 F!FETNIM has the potential to detect tumor hypoxia and is indicated to be less neurotoxic.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: March 17, 1998
    Assignee: Wallace Technologies
    Inventors: Sidney Wallace, David J. Yang, Abdallah Cherif
  • Anthracycline analogues bearing latent alkylating substituents
    Patent number: 5196522
    Abstract: The present invention is a compound having the structure ##STR1##Work relating to the development of the present invention was supported by Grant CA 42708 from the National Institutes of Health, DHHS. This support gives the United States Government certain rights in the present invention .
    Type: Grant
    Filed: November 1, 1990
    Date of Patent: March 23, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: David Farquhar, Abdallah Cherif